Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sage Therapeutics

7.43
+0.06000.81%
Post-market: 7.450.0200+0.27%17:08 EDT
Volume:616.54K
Turnover:4.59M
Market Cap:456.80M
PE:-1.13
High:7.54
Open:7.33
Low:7.33
Close:7.37
Loading ...

Hold Rating on SAGE Therapeutics Amid Strong Zurzuvae Demand and Strategic Shifts

TIPRANKS
·
30 Oct 2024

SAGE Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary

Reuters
·
30 Oct 2024

Hold Rating on SAGE Therapeutics Due to Stable Performance and High-Risk Prospects

TIPRANKS
·
30 Oct 2024

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
30 Oct 2024

Stock Track | Sage Therapeutics Stock Plunges After Halting Zuranolone MDD Program, ZULRESSO Discontinuation

Stock Track
·
30 Oct 2024

Sage Therapeutics Q3 2024 GAAP EPS $(1.53) Misses $(1.52) Estimate, Sales $11.871M Beat $10.802M Estimate

Benzinga
·
30 Oct 2024

BRIEF-SAGE Therapeutics Q3 Product Revenue USD 843 Thousand

Reuters
·
30 Oct 2024

Sage Therapeutics Inc: Anticipates Operating Expenses Will Decrease in 2025 Relative to 2024

THOMSON REUTERS
·
30 Oct 2024

Sage Therapeutics Qtrly Net Loss per Share - Basic & Diluted $1.53

THOMSON REUTERS
·
30 Oct 2024

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

THOMSON REUTERS
·
30 Oct 2024

Sage Therapeutics Inc Q3 Shr View $-1.53 -- Lseg Ibes Data

THOMSON REUTERS
·
30 Oct 2024

Sage Therapeutics : Zulresso Use Will Continue to Decrease and Has Decided to No Longer Make Zulresso Commercially Available as of Dec 31

THOMSON REUTERS
·
30 Oct 2024

Sage Therapeutics Inc: Does Not Anticipate Receipt of Any Milestone Payments From Collaborations in Remainder of 2024

THOMSON REUTERS
·
30 Oct 2024

Sage Therapeutics Q3 Product Revenue USD 843 Thousand

THOMSON REUTERS
·
30 Oct 2024

SAGE Therapeutics Inc expected to post a loss of $1.53 a share - Earnings Preview

Reuters
·
27 Oct 2024

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Zacks
·
23 Oct 2024

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks
·
22 Oct 2024

Cautious Outlook on SAGE Therapeutics Amid Strategic Reorganization and Uncertain Pipeline Prioritization

TIPRANKS
·
21 Oct 2024

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

Zacks
·
19 Oct 2024

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline

GuruFocus.com
·
18 Oct 2024